Algert Global LLC Acquires Shares of 21,447 Organogenesis Holdings Inc. (NASDAQ:ORGO)

Algert Global LLC bought a new position in Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 4th quarter, HoldingsChannel reports. The fund bought 21,447 shares of the company’s stock, valued at approximately $69,000.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. boosted its holdings in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock worth $9,443,000 after purchasing an additional 1,035,120 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after purchasing an additional 442,772 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Organogenesis by 31.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after purchasing an additional 255,600 shares during the last quarter. Northern Trust Corp grew its stake in Organogenesis by 2.9% during the 4th quarter. Northern Trust Corp now owns 616,089 shares of the company’s stock worth $1,971,000 after buying an additional 17,196 shares during the last quarter. Finally, Norges Bank bought a new position in Organogenesis during the 4th quarter worth $1,543,000. 49.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley boosted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Price Performance

NASDAQ ORGO opened at $3.15 on Wednesday. The company has a 50-day moving average price of $4.54 and a two-hundred day moving average price of $3.91. The stock has a market cap of $399.59 million, a price-to-earnings ratio of -52.50 and a beta of 1.85. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52 week low of $2.28 and a 52 week high of $6.71.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). The business had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. Analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 36.90% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.